IQVIA Holdings Inc. $IQV Shares Sold by Lazard Asset Management LLC

Lazard Asset Management LLC lowered its position in IQVIA Holdings Inc. (NYSE:IQV) by 2.0% during the first quarter, Holdings Channel.com reports. The institutional investor owned 1,858,834 shares of the medical research company’s stock after selling 38,116 shares during the period. Lazard Asset Management LLC’s holdings in IQVIA were worth $317,005,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently bought and sold shares of IQV. Apella Capital LLC increased its stake in shares of IQVIA by 5.1% in the first quarter. Apella Capital LLC now owns 1,196 shares of the medical research company’s stock worth $211,000 after acquiring an additional 58 shares during the period. Quadrant Capital Group LLC boosted its holdings in IQVIA by 1.3% in the fourth quarter. Quadrant Capital Group LLC now owns 4,792 shares of the medical research company’s stock valued at $1,080,000 after purchasing an additional 60 shares during the last quarter. Brookstone Capital Management grew its position in IQVIA by 2.2% during the 4th quarter. Brookstone Capital Management now owns 2,931 shares of the medical research company’s stock worth $661,000 after purchasing an additional 63 shares during the period. Private Advisor Group LLC raised its stake in shares of IQVIA by 1.0% during the 3rd quarter. Private Advisor Group LLC now owns 6,122 shares of the medical research company’s stock valued at $1,163,000 after buying an additional 63 shares during the last quarter. Finally, Keybank National Association OH lifted its holdings in shares of IQVIA by 0.7% in the 4th quarter. Keybank National Association OH now owns 9,103 shares of the medical research company’s stock valued at $2,052,000 after buying an additional 67 shares during the period. 89.62% of the stock is owned by hedge funds and other institutional investors.

IQVIA Trading Up 0.1%

Shares of IQVIA stock opened at $208.22 on Monday. The firm has a market capitalization of $34.75 billion, a price-to-earnings ratio of 25.80, a PEG ratio of 1.87 and a beta of 1.20. IQVIA Holdings Inc. has a fifty-two week low of $154.50 and a fifty-two week high of $247.04. The company has a debt-to-equity ratio of 2.20, a quick ratio of 0.75 and a current ratio of 0.75. The stock has a 50 day moving average of $188.23 and a 200 day moving average of $187.05.

IQVIA (NYSE:IQV) last posted its earnings results on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, beating analysts’ consensus estimates of $2.83 by $0.07. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The company had revenue of $4.15 billion for the quarter, compared to the consensus estimate of $4.10 billion. During the same quarter in the previous year, the business earned $2.70 earnings per share. The company’s revenue for the quarter was up 8.4% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. As a group, research analysts predict that IQVIA Holdings Inc. will post 11.57 earnings per share for the current year.

IQVIA declared that its Board of Directors has authorized a stock buyback program on Thursday, May 7th that authorizes the company to buyback $2.00 billion in shares. This buyback authorization authorizes the medical research company to reacquire up to 6.8% of its shares through open market purchases. Shares buyback programs are usually an indication that the company’s board of directors believes its stock is undervalued.

Analysts Set New Price Targets

A number of brokerages have recently commented on IQV. Weiss Ratings upgraded IQVIA from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, July 15th. Robert W. Baird upped their price target on shares of IQVIA from $230.00 to $249.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 1st. Deutsche Bank Aktiengesellschaft set a $240.00 target price on shares of IQVIA in a research report on Thursday, July 9th. HSBC restated a “buy” rating and set a $240.00 target price on shares of IQVIA in a report on Monday, July 6th. Finally, Morgan Stanley reaffirmed an “equal weight” rating and issued a $200.00 price target (down from $225.00) on shares of IQVIA in a report on Wednesday, June 17th. Thirteen equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $225.71.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.